Novo Nordisk A/S
NVO
$65.16
$2.544.06%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 14.65B | 13.79B | 13.05B | 12.99B | 12.15B |
| Total Depreciation and Amortization | 1.21B | 1.29B | 1.34B | 1.21B | 1.03B |
| Total Amortization of Deferred Charges | 36.44M | 30.75M | 30.75M | 30.75M | 30.75M |
| Total Other Non-Cash Items | 3.47B | 5.30B | 2.15B | 1.13B | 4.54B |
| Change in Net Operating Assets | -1.78B | -3.20B | 166.70M | -1.73B | -1.92B |
| Cash from Operations | 17.59B | 17.21B | 16.73B | 13.62B | 15.83B |
| Capital Expenditure | -6.83B | -5.89B | -4.95B | -4.30B | -3.74B |
| Sale of Property, Plant, and Equipment | 4.50K | 147.40K | -- | -- | -- |
| Cash Acquisitions | -11.74B | -96.39M | -96.39M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.96M | -1.64B | -1.42B | -537.38M | -2.63B |
| Cash from Investing | -18.53B | -7.62B | -6.47B | -4.84B | -6.37B |
| Total Debt Issued | 79.39B | 34.63B | 34.51B | -- | -- |
| Total Debt Repaid | -6.34B | -6.26B | -5.99B | -1.31B | -1.47B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -20.18B | -22.45B | -26.19B | -27.56B | -29.92B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -6.45B | -6.45B | -6.12B | -6.12B | -4.60B |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 1.94B | 0.00 |
| Cash from Financing | 1.12B | -5.61B | -5.79B | -10.04B | -9.17B |
| Foreign Exchange rate Adjustments | 63.66M | -68.99M | 43.34M | 27.78M | -16.52M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 241.41M | 3.92B | 4.51B | -1.23B | 275.94M |